The FDA has rejected a rare blood disease candidate from Disc Medicine, a compound that been granted expedited review...
FDA rejected Disc Medicine's rare blood disease candidate despite expedited priority-voucher review, blocking its immediate approval pathway.
Why it mattersFDA rejection of Disc Medicine's rare blood disease candidate demands repricing of hematology program valuations and contingency planning.